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Abstract
Background: Despite the widespread use of antipsychotics, little is known of the molecular bases behind the action of 
antipsychotic drugs. A genome-wide study is needed to characterize the genes that affect the clinical response and their 
adverse effects.
Methods: Here we show the analysis of the blood transcriptome of 22 schizophrenia patients before and after medication 
with atypical antipsychotics by next-generation sequencing.
Results: We found that 17 genes, among the 21 495 genes analyzed, have significantly-altered expression after medication (p-
value adjusted [Padj] <0.05). Six genes (ADAMTS2, CD177, CNTNAP3, ENTPD2, RFX2, and UNC45B) out of the 17 are among the 
200 genes that we characterized with differential expression in a previous study between antipsychotic-naïve schizophrenia 
patients and controls (Sainz et al., 2013). This number of schizophrenia-altered expression genes is significantly higher than 
expected by chance (Chi-test, Padj 1.19E-50), suggesting that at least part of the antipsychotic beneficial effects is exerted by 
modulating the expression of these genes. Interestingly, all six of these genes were overexpressed in patients and reverted to 
control levels of expression after treatment. We also found a significant enrichment of genes related to obesity and diabetes, 
known adverse affects of antipsychotics.
Conclusions: These results may facilitate understanding of unknown molecular mechanisms behind schizophrenia symptoms 
and the molecular mechanisms of antipsychotic drugs.
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Introduction
Schizophrenia is a severe and chronic mental disorder whose 
onset typically occurs in late adolescence to young adulthood. 
The lifetime risk of schizophrenia ranges from 0.3% to 0.66% 
worldwide, and up to 2.3% if other psychotic disorders are consid-
ered. The standard of schizophrenia treatment is antipsychotic 
medications (Insel, 2010). The mechanism of action of these 
medications tends to block receptors in the brain’s dopamine 
D2 pathways (Jones and Pilowsky, 2002). Antipsychotics only 
achieve clinical improvement in a percentage of patients and 
also are highly associated with adverse effects (van Os and 
Kapur, 2009). Lifetime antipsychotic treatment is frequently 
required to prevent illness relapses and to maintain functional-
ity. The use of antipsychotics also represents a huge economic 
burden to society. Studies of clinical response variability have 
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established the importance of functional mutations detected in 
CYP metabolic enzymes (Nebert and Dieter, 2000). Other stud-
ies focused in genes related to neurotransmitter (dopamine and 
serotonin) pathways traditionally involved with schizophrenia 
have not clarified the molecular basis of the clinical response.
Alterations in gene expression could provide relevant infor-
mation on the molecular basis of the disease and the mecha-
nisms of action of the antipsychotics (Chana et  al., 2013). 
Post-mortem studies of gene expression obtained from brains 
are affected by the period of time from death to sample col-
lection, by the change in mRNA levels caused by all possible 
medication given to the individuals, and by the number of genes 
altered by the agony of death. However, a viable alternative is 
the study of mRNA levels in lymphocytes from living individu-
als, which are free of the variability observed in post-mortem 
studies (Czermak et  al., 2004). It has been reported that the 
expression level of genes encoding neurotransmitter receptors 
and other proteins is similar in peripheral blood lymphocytes 
and in the central nervous system (Glatt et al., 2005).
To identify genes targeted by atypical antipsychotics, we 
investigated the expression profiles altered by these drugs. Here 
we report the first study, to our knowledge, of gene differential 
expression in blood between drug-naïve schizophrenia patients 
and the same patients after treatment with atypical antipsy-
chotics using next-generation sequencing data. We hypothesize 
that this information could be used to identify biomarkers for 
the disease, to monitor the effect of the antipsychotics, and for 
drug repositioning and development. We sequenced total mRNA 
of a cohort of 22 individuals (Table 1) before treatment and the 
same individuals 3 months after treatment started. All patients 
showed improved symptoms after treatment (Table 2). These 22 
patients are part of a larger cohort used for a previous case/con-
trol study (Sainz et al., 2013).
Methods
Study Setting
The cohort analyzed in this study (Table 1) was obtained from 
an ongoing epidemiological and three-year longitudinal inter-
vention program of first-episode psychosis (PAFIP) conducted 
at the outpatient clinic and the inpatient unit at the University 
Hospital Marques de Valdecilla, Cantabria, Spain (Pelayo-Teran 
et al., 2008). Conforming to international standards for research 
ethics, the research in this article was approved by the Cantabria 
Ethics Institutional Review Board. Patients meeting inclusion 
criteria and their families provided written informed consent 
to be included in the PAFIP. The biological samples of patients 
included in the study were provided by the Valdecilla biobank.
Subjects
All referrals to PAFIP were screened for patients who met the 
following criteria: (1) 15–60  years; (2) living in the catchment 
area (Cantabria); (3) experiencing their first episode of psycho-
sis; (4) no prior treatment with antipsychotic medication or, if 
previously treated, a total lifetime of adequate antipsychotic 
treatment of less than 6 weeks; and (5) DSM-IV criteria for schiz-
ophrenia, schizophreniform disorder, schizoaffective disorder, 
or brief psychotic disorder. Patients were excluded for any of the 
following reasons: (1) meeting DSM-IV criteria for drug depend-
ence; (2) meeting DSM-IV criteria for mental retardation; or (3) 
having a history of neurological disease or head injury. The diag-
noses were confirmed using the Structured Clinical Interview 
for DSM-IV, carried out by an experienced psychiatrist 6 months 
after the baseline visit. Our operational definition for a first 
episode of psychosis included individuals with a non-affective 
psychosis (meeting the inclusion criteria defined above) who 
have not previously received antipsychotic treatment regardless 
of the duration of psychosis. Twenty-two individuals, who gave 
written consent to their participation in the program, fulfilled 
inclusion criteria at 6 months, and had mRNA samples at base-
line and at 3 months, were included in our analyses.
Premorbid and Sociodemographic Variables
Premorbid and sociodemographic information was recorded 
from patients (Table  1), relatives, and medical records. Age of 
onset of psychosis was defined as the age when the first con-
tinuous (present most of the time) psychotic symptom emerged. 
Duration of untreated illness was defined as the time from the 
first unspecific symptoms related to psychosis (for such a symp-
tom to be considered, there could be no return to the previous, 
stable level of functioning) to initiation of adequate antipsy-
chotic drug treatment. Duration of untreated psychosis was 
defined as the time from the first continuous (present most of 
the time) psychotic symptom to initiation of adequate antipsy-
chotic drug treatment. Information about alcohol, cannabis, and 
tobacco consumption was converted into binary variables and 
coded for either the presence or absence of use.
Study Design
This is a prospective, randomized, flexible-dose, open-label study. 
We used a simple randomization procedure. At study intake, all 
patients were antipsychotic-naïve and were randomized to ari-
piprazole (n = 13), risperidone (n = 3), olanzapine (n = 1), quetia-
pine (n = 3), or ziprasidone (n = 2). Dose ranges were 5–30 mg/
day aripiprazole, 2–6 mg/day risperidone, 5–20 mg/day olanzap-
ine, 40–160 mg/day ziprasidone, and 100–600 mg/day quetiapine. 
A rapid titration schedule (5 days) was used until the optimal dose 
was reached, unless severe side effects occurred. At the treating 
physician´s discretion, the dose and type of antipsychotic medi-
cation could be changed based on clinical efficacy and the pro-
file of side effects during the follow-up period. Antimuscarinic 
Table  1. Sociodemographic and Clinical Characteristics of Study 
Individuals
Characteristics
Total
 (n = 22)
Mean SD
Age at admission (years) 32.1 10.6
Age at psychosis onset (years) 31.7 10.5
Duration of untreated psychosis (months) 4.5 8.0
Duration of untreated illness (months) 7.8 10.2
n %
Sex
 Male 8 36.4
 Female 14 63.6
Race
 Caucasians 22 100
Family history of psychosis (yes) 7 31.8
Tobacco use at intake (yes) 13 59.1
Cannabis use at intake (yes) 7 31.8
Alcohol use at intake (yes) 11 50.0
Crespo-Facorro et al. | 3
medication, lormetazepam, and clonazepam were permitted 
for clinical reasons. No antimuscarinic agents were adminis-
tered prophylactically. Antidepressants and mood stabilizers 
were permitted if clinically needed. At the 3-month follow-up, 
patients were on: aripiprazole (n = 9), risperidone (n = 5), olan-
zapine (n = 4), quetiapine (n = 1), ziprasidone (n = 2), and risperi-
done depot (n = 1). The mean daily dose of antipsychotics during 
follow-up was 181.72 (93.97) mg/day of chlorpormazine-equiva-
lent doses. The mean daily dose of antipsychotics at 3 months 
was 163.64 (86.47) mg/day of chlorpormazine-equivalent doses. 
A more detailed description of medication intake during the fol-
low-up period is available upon request.
Clinical Assessment
The severity of the Clinical Global Impression (CGI; 3)  scale, 
the Brief Psychiatric Rating Scale (BPRS; expanded version of 
24 items), the Scale for the Assessment of Positive symptoms 
(SAPS), the Scale for the Assessment of Negative symptoms 
(SANS), the Calgary Depression Scale for Schizophrenia (CDSS) 
and the Young Mania Rating Scale (YMRS) were used to evalu-
ate clinical symptomatology. The same trained psychiatrist (Dr 
Crespo-Facorro) completed all clinical assessments. The severity 
of symptoms at baseline and at 3 months and the percentage of 
change at 3 months are reported in Table 2 (a reduction in total 
scores means clinical improvement).
The analysis of clinical efficacy reveals that there was a sig-
nificant improvement of general psychopathology (assessed by 
the BPRS total score change at 3  months) and positive symp-
toms (hallucinations, delusions, positive formal thought disor-
ders, bizarre behavior; assessed by SAPS total score changes at 
3 months; Table 2). The patients were defined as responders to 
the optimum dose of antipsychotic at 3 months if there was a 
>50% reduction of the BPRS total score compared to intake. The 
rate of responders at 3 months was 95.55%.
Laboratory Assessments
Blood samples were assessed for biochemical and hematological 
parameters. To minimize the effects of diet and technique, blood 
samples were obtained from fasting subjects from 08:00 to 10:00 
hours by the same personnel and in the same setting. A detailed 
description of methodology followed to assess hematological and 
biochemical variables (data available upon request). No patient 
had a chronic inflammation or infection, or was taking medica-
tion that might influence the results of blood tests. Smoking sta-
tus and alcohol use were recorded at baseline. Anthropometric, 
hematological, and metabolic variables at baseline and 3 months, 
and changes at 3 months, are described in Table 3.
RNA Extraction
Total RNA was extracted from blood using the Tempus™ 
Blood RNA Tube and Tempus™ Spin RNA Isolation Kit (Applied 
Biosystems) using the manufacturer’s protocols. To define 
expression profiles, a key factor is that the RNA is intact. To select 
Table 2. Psychopathology at Baseline and 3 Months, and Magnitude of the Change
Variable
Total (n = 22)
Baseline 3 months 3-month change from baseline
%Mean SD Mean SD Mean SD
CGI total score 6.0 0.8 2.3 1.1 -3.6 1.6 n/a
BPRS total score 53.0 9.1 28.7 3.9 -24.3 10.2 -45.9
SANS total score 5.8 5.7 4.0 3.7 -1.8 6.9 -30.7
SAPS total score 12.0 3.6 0.4 1.0 -11.7 3.9 -97.0
CDSS total score 2.0 3.1 1.4 3.6 -0.6 5.3 -30.2
YMRS total score 10.9 6.7 0.4 1.0 -10.5 6.9 -96.3
BPRS: Brief Psychiatric Rating Scale; CDSS: Calgary Depression Rating Scale for Schizophrenia; CGI: Clinical Global Impression; SANS: Scale for the Assessment of 
Negative Symptoms; SAPS: Scale for the Assessment of Positive Symptoms; SD: standard deviation; YMRS: Young Mania Rating Scale.
Table 3. Blood and Metabolic Parameters of the 22 Patients at Baseline and at 3 Months
Variable
Total (N=22)
Baseline 3 months 3-month change from baseline
%Mean SD Mean SD Mean SD
BMI (kg/m2) 22.5 2.7 24.0 2.5 1.4 2.2 6.4
Weight (kg) 62.9 11.0 66.9 10.1 4.0 5.9 6.3
Leukocytes (10^3 µ/L) 7.6 1.8 6.6 1.3 -1.0 2.2 -13.4
Hemoglobin (g/dl) 14.1 1.0 14.0 1.0 -0.1 1.2 -0.5
Glucose (mg/dl) 86.1 12.9 84.4 7.2 -1.7 14.3 -2.0
GGT (U/l) 14.4 7.4 15.8 9.0 1.4 7.7 9.5
Cholesterol (mg/dl) 176.3 30.2 185.6 33.7 9.3 30.2 5.3
Triglycerides (mg/dl) 73.4 26.0 88.9 51.0 15.6 53.7 21.2
HDL cholesterol (mg/dl) 59.4 17.9 58.0 11.8 -1.4 14.9 -2.4
CRP (mg/dl) 0.5 1.1 0.1 0.2 -0.3 1.1 -75.4
BMI: body mass index; CRP: C-reactive protein; GGT: gamma-glutamytransferease; HDL: high density lipoprotein; SD: standard deviation.
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only RNA with good quality, the RNA Integrity Number (RIN) was 
characterized with a Bioanalyzer (Agilent Technologies) and 
samples with a RIN of at least 7.2 were selected. The selected 
samples have RINs that range from 7.2 to 9.8 with an average of 
8.5. Overall, the rate of samples from patients with a RIN equal 
to or higher than 7.2 was slightly higher than 89%.
RNA Next Generation Sequencing
The mRNA obtained from blood was sequenced using a Genome 
Analyzer IIx from Illumina. Total RNA was extracted from periph-
eral blood of each individual. The mRNA was isolated from the 
total RNA and, once transformed into cDNA, was fragmented by 
sonication. Fragments of 300 bp on average were selected to con-
struct the libraries for sequencing. The libraries to sequence were 
constructed using the reagents according to the indications of 
the manufacturer (Illumina). Single-end sequences of 35 nucleo-
tides were produced using a Genome Analyzer IIx (Illumina). 
Alignment of the reads was performed in an Simple Linux Utility 
for Resource Management High Performance Computer server 
running Tophat 2.0.6 with default options (Trapnell et al., 2009). 
Tophat aligns RNA-Seq reads to genomes using the Bowtie 2.0.2 
alignment program (Langmead et al., 2009), and then analyzes 
the mapping results to identify splice junctions between exons.
Differential Expression Statistical Analyses
Bedtools 2.17.0 (multicov option; Quinlan and Hall, 2010) was 
used to count the amount of reads mapped to each gene. The 
Reference Sequence gene coordinates were defined using the 
RefFlat file from the UCSC Genome Bioinformatics Site (retrieved 
February 28, 2014). DESeq 1.10.1 package (Anders and Huber, 
2010), setting up fit-only as fitting method, was used to test for 
differential expression using gene-count data.
Validation of Expression Data Using quantitative 
reverse transcription PCR
To validate the expression data obtained by RNA-Seq, we per-
formed quantitative reverse transcription PCR amplification of 
10 of the genes that were found to have differential expression 
between cases and controls (Sainz et al., 2013) on 30 randomly 
selected samples (15 cases before medication and 15 controls). We 
used pre-designed Taqman probes (Life technologies) using the 
manufacturer’s instructions for LAMP3 (Hs00180880_m1), RFX2 
(Hs01100925_m1), CTAG2 (Hs00535628_m1), GPR128 (Hs00262184_
m1), IFI27 (Hs01086373_g1), ADAMTS2 (Hs01029111_m1), BRS3 
(Hs00179951_m1), MSLN (Hs00245879_m1), RSAD2 (Hs00369813_
m1), and IFI144L (Hs00119115_m1) using GADPH (Hs02758991_g1) 
as the control. Overall, we obtained a correlation ratio of 87.15% 
between the two technologies, with gene-individual correlation 
ratios varying from 75.0% (CTAG2) to 99.9% (MSLN).
Results
We found 17 genes with significant differential expression 
(Table 4) after adjusting for multiple testing (Padj Value <0.05) 
in the 21 495 human genes analyzed (Supplementary Table 1). In 
the previous study (Sainz et al., 2013) we found 200 genes with 
differential expression between schizophrenia patients and con-
trols (36 schizophrenic, drug-naïve patients and 40 controls). Six 
of the differentially-expressed genes between untreated/treated 
patients (ADAMTS2, CD177, CNTNAP3, ENTPD2, RFX2, and 
UNC45B) also have differential expression between drug-naïve 
patients/controls. The 6 schizophrenia-related genes that we 
found in our previous study case/control (Sainz et al., 2013) rep-
resent a large fraction (35.29%) of the 17 genes that we found 
with differential expression after medication with antipsychot-
ics. This fraction is significantly higher (approximately 39-fold) 
than the one expected by chance (Chi test, p-value = 1.19E-50). 
All six genes that we previously implicated with schizophrenia 
have their expression levels significantly higher in patients than 
in controls and, after medication with atypical antipsychotics, 
their expression reverted to control levels. Normalized data that 
reflects this reversion is depicted in Figure 1. These results sup-
port the theory that the expression of these six genes could be 
modulated by the drugs and the possibility that they are impli-
cated in the positive symptoms of the disease (hallucinations, 
delusions, positive formal thought disorders, bizarre behavior) 
that are improved by the antipsychotics.
To determine if the 17 genes with altered expression by 
antipsychotics were enriched for certain biological processes, 
molecular functions, or cellular localizations, data from the Gene 
Ontology Repository was analyzed using the tool FatiGO (http://
babelomics.bioinfo.cipf.es/). We found enrichment for the cellu-
lar components—extracellular matrix and proteinaceous extra-
cellular matrix—which are involved in many functions, such as 
segregating tissues from one another and regulating intercellu-
lar communication. The fraction of genes modulated by antip-
sychotics in both categories represents 23.53%, while expected 
fractions are 1.49% and 1.59% respectively (Padj value = 0.015 for 
both categories). The four genes included in these categories are 
ENTPD2, MMP8, ADAMTS2, and CRISP3. Gene Set Enrichment 
Analysis did not show any pathway enriched for the 17 genes 
with differential expression.
Eight genes out of the 17 (LTF, OLFM4, ADAMTS2, RFX2, ALPL, 
MMP8, ABCA13, and INSC) appear to associate, either as reported 
or as mapped gene, with 24 diseases/traits in the Genome Wide 
Figure 1. Schizophrenia differential expression genes reverted by antipsychotic 
medications. Base mean: mean of normalized counts, averaged over all samples 
for each condition; controls: normalized expression level of controls; untreated 
cases: normalized expression level of untreated patients; treated cases: normal-
ized expression level from the patients, obtained after 3 months of treatment.
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Association Studies Catalog (GWAS; retrieved February 28, 2014). 
The association with diseases includes schizophrenia and bipo-
lar disorder (RFX2; Wang et al., 2010), time to onset of attention 
deficit hyperactivity disorder (ADAMTS2; Lasky-Su et al., 2008), 
response to amphetamine (ABCA13; Hart et al., 2012), AIDS pro-
gression (LTF; Troyer et al., 2011), metabolic traits (ALPL; Suhre 
et  al., 2011), obesity (OLFM4; Bradfield et  al., 2012), obesity-
related traits (INSC; Comuzzie et al., 2012), and visceral adipose 
tissue adjusted for body mass index (ADAMTS2; Fox et al., 2012), 
among other disease-traits. The three genes associated with 
obesity represent a fraction (3 out of 8 or 37.5%) larger than the 
fraction of genes present in the complete GWAS Catalog (15.5%).
According to the scientific literature deposited in the Gene 
Reference into Function (GeneRIF) repository at the National 
Center for Biotechnology Information (retrieved February 28, 
2014), 15 out of the 17 differential expression genes are anno-
tated for disease or functionality in 719 publications. Among 
these genes, ABCA13 has been implicated in schizophrenia, 
bipolar disorder, and depression (Knight et al., 2009). The 15 dif-
ferential-expression genes annotated are significantly enriched 
for two known adverse effects caused by the atypical antipsy-
chotics: obesity and diabetes. Five genes—GPER (Haas et  al., 
2009), LTF (Moreno-Navarrete et  al., 2013), MMP8 (Belo et  al., 
2009), OLR1 (Brinkley et  al., 2008), and OLFM4 (Bradfield et  al., 
2012)—have been implicated with obesity: these genes repre-
sent 33.33% of the differential-expression genes, while in the 
complete GeneRIF repository there are only 3.99% of the human 
genes annotated for obesity (Fisher; p  =  0.0002). Four of the 
genes—ALPL (Kanazawa et  al., 2009), LTF (Vengen et  al., 2010), 
MMP8 (van der Zijl et al., 2010), and OLR1 (Tan et al., 2008)—have 
been implicated with diabetes: these genes represent 26.67% of 
the differential-expression genes, while 7.88% (Fisher; p = 0.026) 
is expected. Moreover, it is known that all antipsychotics tend 
to block receptors in the brain’s dopamine pathways, and that 
estrogen increases the concentration of neurotransmitters such 
as dopamine at neuronal synapses and their receptors, affecting 
their release, reuptake, and enzymatic inactivation (Mcewen and 
Alves, 1999). We found a significant enrichment of genes related 
to estrogen, including an estrogen receptor: GPER (Revankar 
et al., 2005), LTF (Teng et al., 2002), and OLFM4 (Dassen et al., 2010) 
represent a fraction of 20.00% of the total, while we expect to find 
4.3% (Fisher; p = 0.026). Previously, we described an alteration of 
inflammatory genes in schizophrenia (Sainz et al., 2013): we also 
find in GeneRIF an enrichment of inflammatory genes among 
the genes with their expression modulated by the atypical antip-
sychotics. There are six genes—ALPL (Cheung et al., 2008), GPER 
(Chakrabarti and Davidge, 2012), LTF (Weinberg, 2001), MMP8 
(Leppilahti et  al., 2011), OLR1 (Takanabe-Mori et  al., 2013) and 
CRISP3 (Plager et al., 2010)—related to inflammation, represent-
ing 40.00%, while only 10.97% is expected (Fisher; p = 0.005). These 
results are encouraging, though we recognize that it is really dif-
ficult to assess enrichment for such a small number of genes.
Discussion
We characterized 17 genes with differential expression in schiz-
ophrenia patients before and after medication. Previously, we 
characterized 200 genes with differential expression between 
non-medicated schizophrenia patients and controls. Six of the 
genes with expression modulated by the atypical antipsychotic 
medication also have altered expression in our case/control 
study of schizophrenia. The six genes with altered expression 
in both studies are overexpressed in schizophrenia and reverted 
to normal levels of expression after medication with atypical 
antipsychotics. The fact that the expression of these six genes 
is downregulated by antipsychotics and that they are over-
expressed in schizophrenia is not proof of causality, but does 
make them candidates to have a relationship with some of the 
psychotic symptoms of the disease. It is known that the posi-
tive symptoms of the disease, such as hallucinations, delusions, 
and mood swings, are improved by the antipsychotics, result-
ing in a lower risk of suicide, better functional capacity, and an 
improved quality of life (Kapur and Remington, 2001). Given 
that more than 95% of the individuals had a good response to 
medication, we can hypothesize that the six genes reported are 
related functionally to these positive symptoms of psychosis. 
It is of note that nearly 95% of the patients were categorized 
as good responders to antipsychotic treatment. It is likely that 
Table 4. Genes with Significant Differential Expression in Schizophrenia Patients Before and After Treatment with Antipsychotics
Gene ID Gene symbol Base mean Base mean untreated Base mean treated Fold change Log2 fold change Pval Padj
9509 ADAMTS2 23.86 43.58 4.14 0.10 -3.39 1.93E-45 3.77E-41
57126 CD177 125.21 182.64 67.79 0.37 -1.43 4.16E-15 4.06E-11
146862 UNC45B 228.32 355.59 101.05 0.28 -1.82 9.36E-13 6.09E-09
10321 CRISP3 115.80 67.59 164.01 2.43 1.28 4.87E-09 2.38E-05
85495 RPPH1 26.05 39.65 12.45 0.31 -1.67 3.21E-07 0.00125
249 ALPL 4431.75 5880.32 2983.17 0.51 -0.98 1.49E-06 0.00345
4317 MMP8 183.67 123.53 243.80 1.97 0.98 1.80E-06 0.00345
4973 OLR1 33.13 20.86 45.40 2.18 1.12 1.41E-06 0.00345
10562 OLFM4 137.50 93.08 181.92 1.95 0.97 1.94E-06 0.00345
1088 CEACAM8 187.21 127.35 247.08 1.94 0.96 1.60E-06 0.00345
154664 ABCA13 92.18 61.89 122.47 1.98 0.98 1.37E-06 0.00345
5990 RFX2 520.36 681.17 359.54 0.53 -0.92 7.00E-06 0.01051
4057 LTF 1632.35 1170.32 2094.38 1.79 0.84 6.51E-06 0.01051
2852 GPER1 28.34 36.77 19.90 0.54 -0.89 1.01E-05 0.01408
79937 CNTNAP3 195.23 249.03 141.42 0.57 -0.82 1.68E-05 0.02189
954 ENTPD2 29.04 36.51 21.57 0.59 -0.76 2.52E-05 0.03069
387755 INSC 31.74 41.60 21.87 0.53 -0.93 3.83E-05 0.04395
Base mean: mean normalized counts, averaged over all samples from both conditions; base mean untreated: mean normalized counts from condition A; base mean 
treated: mean normalized counts from condition B; fold change: fold change from condition A to B; log2 fold change: the logarithm, to basis 2, of the fold change; 
Pval: p-value for the statistical significance of this change; Padj: p-value adjusted for multiple testing with the Benjamini-Hochberg procedure, which controls false 
discovery rate.
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the method of calculation we followed to assess the reduc-
tion of symptom severity may explain, at least in part, the high 
response. As has been proposed recently (Leucht et  al., 2010; 
Obermeier et al., 2010), the calculation of responder rates based 
on percentage reduction of the BPRS total score from baseline 
has to be carried out after subtracting the 24 minimum points of 
the total score (24 points means no symptoms). Previous publica-
tions, in which the percentage reduction has not been correctly 
calculated, would have found lower numbers of responders. In 
addition, the fact that our patients were included in an inten-
sive clinical program for treatment of first-episode individuals 
may have influenced the high rate of responders. All of the 17 
genes characterized with expression significantly altered by the 
atypical antipsychotics are good candidates to be responsible 
for some of the adverse effects associated with the drugs: sig-
nificant weight gain, increased risk of diabetes and stroke, blood 
clots, sexual dysfunction, and hyperlipidemia (Ucok and Gaebel, 
2008). Our analysis of the results, with the caveat that it is based 
on a small number of genes, supports this hypothesis: accord-
ing to the scientific literature, there is a significant enrichment 
of genes related to diabetes and obesity among the differential-
expression genes. We also found an enrichment of genes associ-
ated to obesity or related traits according to the data deposited 
in the GWAS Catalog. This suggests that some of the genes 
with expressions altered by the atypical antipsychotics could 
be causative of obesity and diabetes. Additionally, the genes 
characterized with altered expressions are consistent with the 
known molecular mechanisms of the antipsychotic action: we 
find that there is a significant enrichment of genes related to 
estrogen that regulate the levels of dopamine receptors, and it is 
known that antipsychotics interact with receptors in the brain’s 
dopamine pathways (Seeman, 2002).
We recognize that this study has the limitation of a small 
sample size and that a larger study is needed. But despite this 
limitation, we were able to obtain significant results, which 
could help to predict the effects of the atypical antipsychot-
ics currently used in the clinical practice by monitoring the 
expression levels of the reported genes. We provide six can-
didate genes for schizophrenia that could be involved in 
the positive symptoms improved by the drugs, and a list of 
17 genes that could be responsible for some of their adverse 
effects, such as obesity and diabetes. This information could 
help us not only to better understand schizophrenia, but also 
to develop new drugs and to improve the ones used today 
against psychosis.
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